Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 14/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 10/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415155 | 1.00 | CD274 (0.35) | CD274PDCD1LG2CNR2PDCD1IRAK1 | |
| SCHEMBL2412929 | 0.85 | CD274 (0.36) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2412944 | 0.85 | CD274 (0.36) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL18120941 | 0.85 | CD274 (0.31) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL2412186 | 0.82 | CD274 (0.33) | CD274PDCD1LG2CNR2PDCD1IRAK1 | |
| SCHEMBL2414664 | 0.82 | IRAK4 (0.33) | CD274PDCD1LG2CNR2PDCD1IRAK1 | |
| SCHEMBL2414661 | 0.82 | IRAK4 (0.33) | CD274PDCD1LG2CNR2PDCD1IRAK1 | |
| SCHEMBL2412187 | 0.82 | CD274 (0.33) | CD274PDCD1LG2CNR2PDCD1IRAK1 | |
| SCHEMBL2415555 | 0.81 | IDO1 (0.35) | CD274PDCD1LG2CNR2PDCD1 | |
| SCHEMBL2415553 | 0.81 | IDO1 (0.35) | CD274PDCD1LG2CNR2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2921489-B1 | 2-PYRIDONE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2921489-B1 | 2-PYRIDONE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-9695148-B2 | 2-pyridone compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695148-B2 | 2-pyridone compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695148-B2 | 2-pyridone compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160289208-A1 | 2-PYRIDONE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| US-20160289208-A1 | 2-PYRIDONE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| US-20160289208-A1 | 2-PYRIDONE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| EP-2921489-A1 | 2-PYRIDONE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-2921489-A1 | 2-PYRIDONE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| WO-2014077235-A1 | 2-PYRIDONE COMPOUND | 大正製薬株式会社 (JP) | 2014-05-22 | — | — | WO | disclosed |
| CN-102884047-A | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO LTD | 2013-01-16 | — | — | CN | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2011068211-A1 | 2-PYRIDONE COMPOUNDS | 大正製薬株式会社 (JP) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | CD274 2673/4885PDCD1LG2 2802/4885CNR2 825/4885 |
| US-20160289208-A1 | 2-PYRIDONE COMPOUND | PDXK, MAP4K5, P2RY2 | CD274 2094/4885PDCD1LG2 1884/4885CNR2 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.